A Pilot Study of Pivanex in Patients With Malignant Melanoma

Stopped early · Phase 1/Phase 2

Conditions studied: Malignant Melanoma

In brief

This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.

Key facts

Study ID

NCT00087477

Run by

Titan Pharmaceuticals

People needed

14

Starts

2004-01-01

Expected to finish

2004-08-01

Last updated by the study team

2005-08-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed melanoma, previously treated with chemotherapy or IL-2
• Recurrent or progressive disease after treatment.
• Measurable disease.
• Males and females, age ≥ 18 years.
• Adequate renal function with creatinine ≥ 1.5 mg/dl.
• Adequate liver function with alkaline phosphatase <= 2.5 X upper limit of normal, SGOT and SGPT <= 1.5 X upper limit of normal and total bilirubin <= 1.5 X upper limit of normal.
• Adequate bone marrow function: platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, and absolute neutrophil count (ANC)≥ 1,500 cells/mm3.
• Able to give informed consent.
• Must have discontinued previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity. Localized palliative radiation therapy to non-target lesions is permitted within the four weeks prior to randomization.
• A predicted life expectancy of at least 6 months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

You may not qualify if…

• Receipt of more than three (3) systemic treatment regimens for malignant melanoma (including IL-2).
• A second malignancy within the last 5 years other than curatively treated carcinoma-in-situ or non-melanoma skin cancer.
• Pregnant or lactating females. Females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control.
• Known HIV-positive patients.
• Acute medical problems, such as ischemic heart or lung disease or uncontrolled systemic infection.
• Patients with any underlying medical conditions or circumstance, which would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints.
• Patients receiving investigational agents within 4 weeks of randomization.
• Known allergy to reagents in the study.
• Symptomatic or untreated brain metastases - Patients with brain metastases are eligible if they are clinically and neurologically stable for ≥ 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife, surgical resection) as determined by the investigator and either off corticosteroids or on a stable dose of corticosteroids.

Where it is running

• Mt. Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.